In a commentary published in Clinical Investigation, Hennekens and David J. Bjorkman, M.D., M.S.P.H., dean and executive director of medical affairs for the Charles E. Schmidt College of Medicine consider the emerging
evidence on aspirin in the prevention of colorectal and other cancers and provide advice to doctors.
Not exact matches
On the basis of similar — though admittedly stronger —
evidence, doctors already advise millions of people to take low - dose
aspirin to reduce their risk of having heart attacks and strokes.
However, clinical
evidence supporting the chemopreventive effect of
aspirin therapy
on liver cancer remains limited.
Hennekens and Bjorkman advise doctors that, based
on the current totality of
evidence, in the primary prevention of vascular disease and cancer, any judgments about prescribing long - term
aspirin therapy for apparently healthy individuals should be based
on individual clinical judgments between the doctor and each of his or her patients.
There was no significant difference (p > 0.1) in the prevalence (54 - 72 %) or severity of intestinal inflammation in the 286 patients taking the various NSAIDs apart from those
on aspirin and nabumetone, these having no
evidence of intestinal inflammation.